Drug Profile
Alvespimycin - Kosan Biosciences
Alternative Names: 17-dimethylaminoethylamino-17-demethoxy-geldanamycin; DMAG; KOS-1022; NSC-707545Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Developer Kosan Biosciences
- Class Antineoplastics; Carbamates; Cytostatic antibiotics; Heterocyclic bicyclo compounds
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; HER2 positive breast cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 27 Jun 2008 Kosan Biosciences has been acquired by Bristol-Myers Squibb
- 28 Feb 2008 Discontinued - Phase-I for Acute lymphoblastic leukaemia in USA (IV)
- 28 Feb 2008 Discontinued - Phase-I for Acute myeloid leukaemia in USA (IV)